A Mab A Case Study In Bioprocess Development «Deluxe ›»
If upstream is about growing the protein, downstream is about catching it and cleaning it. This is often the most expensive phase of production due to the high cost of resins and chromatography columns.
The bioprocessing field is in a period of rapid evolution, moving from traditional batch processes toward more efficient, flexible, and cost-effective models.
The production process included a dedicated after elution. A Mab A Case Study In Bioprocess Development
The primary goal of upstream development is to maximize volumetric productivity while ensuring the critical quality attributes (CQAs) of the mAb remain within predefined limits. Cell Line Development
The drug substance was formulated in 20 mM Histidine, 5% Sucrose, 0.02% Polysorbate 80, pH 6.0. Note: Polysorbate 80 was selected over PS20 due to lower hydrolysis risk observed in accelerated stability studies (40°C for 1 month). If upstream is about growing the protein, downstream
The downstream process utilized a standard three-column platform purification template, heavily optimized for this specific mAb's impurity profile.
The findings allow for the creation of a control strategy that ensures consistent production, even with slight variations in raw materials or equipment. The production process included a dedicated after elution
New technologies are accelerating process development and control. The integration of and advanced analytics is enabling real-time monitoring and proactive process control, making processes smarter and more adaptive. Moreover, while most mAbs are produced in CHO cells, microbial systems are being explored as potentially cheaper and faster alternatives, though they face challenges in performing the complex post-translational modifications required for human therapeutic efficacy.
The A Mab case study demonstrates the complexities and challenges involved in bioprocess development for monoclonal antibodies. Through the employment of strategies to overcome these challenges, a robust and scalable bioprocess was developed, and valuable lessons learned were identified. The development of bioprocesses for mAbs requires a multidisciplinary approach, including expertise in cell line development, fermentation, purification, and regulatory compliance. The A Mab case study serves as a model for bioprocess development and highlights the importance of collaboration, process optimization, and regulatory compliance.
Changed from top addition of Na₂CO₃ to a dip-pipe with an efficient mixing zone and implemented pH-stat control with CO₂ sparging . At 2,000L stainless steel bioreactor, aggregation dropped to 1.5%.
The downstream section focuses on removing impurities such as host cell proteins (HCPs) and aggregates. The study highlights the need for validating intermediate hold times (e.g., low-pH hold) to ensure the stability and safety of the mAb during purification. 4. The Role of QbD in Modern Bioprocessing
